Skip to main content
Erschienen in: Cancer Causes & Control 10/2010

01.10.2010 | Original paper

Male infertility and prostate cancer risk: a nested case–control study

verfasst von: Yasir Ruhayel, Aleksander Giwercman, David Ulmert, Lars Rylander, Anders Bjartell, Jonas Manjer, Göran Berglund, Yvonne L. Giwercman

Erschienen in: Cancer Causes & Control | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

The pathogenesis of prostate cancer is unclear, although experimental evidence implicates androgens as playing an important role. Infertile men frequently suffer from some degree of hypogonadism and may hence be hypothesized to be at lower risk of developing prostate cancer than fertile men. To test this hypothesis, we conducted a case–control study nested within “the Malmö Diet and Cancer Study” cohort in Sweden, inviting 661 prostate cancer cases and 661 age-matched controls to participate. Of the 975 (74%) respondents, we excluded 84 childless men with unknown fertility status. Thus, 891 men were included, providing 445 prostate cancer cases and 446 controls. Of these, 841 (94%) men were biological fathers and 50 (6%) men were infertile. Logistic regression showed that the infertile men were at significantly lower risk of being diagnosed with prostate cancer than the fertile men (odds ratio, 0.45; 95% confidence interval, 0.25–0.83). Conditional and unconditional multivariate models, adjusting for socioeconomic, anthropometric, and health-status-related factors, provided similar estimates. We conclude that enduring male infertility is associated with a reduced prostate cancer risk, thus corroborating the theory that normal testicular function, and hence most probably sufficient steroidogenesis, is an important contributing factor to the later development of this malignancy.
Literatur
1.
Zurück zum Zitat Sonnenschein C, Olea N, Pasanen ME, Soto AM (1989) Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res 49:3474–3481PubMed Sonnenschein C, Olea N, Pasanen ME, Soto AM (1989) Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res 49:3474–3481PubMed
2.
Zurück zum Zitat Chen HZ, Kirschenbaum A, Mandeli J, Hollander VP (1992) The effect of dihydrotestosterone and culture conditions on proliferation of the human prostatic cancer cell line LNCaP. Steroids 57:269–275CrossRefPubMed Chen HZ, Kirschenbaum A, Mandeli J, Hollander VP (1992) The effect of dihydrotestosterone and culture conditions on proliferation of the human prostatic cancer cell line LNCaP. Steroids 57:269–275CrossRefPubMed
3.
Zurück zum Zitat Pollard M, Suckow MA (2005) Hormone-refractory prostate cancer in the Lobund-Wistar rat. Exp Biol Med (Maywood) 230:520–526 Pollard M, Suckow MA (2005) Hormone-refractory prostate cancer in the Lobund-Wistar rat. Exp Biol Med (Maywood) 230:520–526
4.
Zurück zum Zitat Bosland MC (2006) Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. Ann N Y Acad Sci 1089:168–176CrossRefPubMed Bosland MC (2006) Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. Ann N Y Acad Sci 1089:168–176CrossRefPubMed
5.
Zurück zum Zitat Pollard M, Luckert PH, Snyder D (1989) Prevention and treatment of experimental prostate cancer in Lobund-Wistar rats. I. Effects of estradiol, dihydrotestosterone, and castration. Prostate 15:95–103CrossRefPubMed Pollard M, Luckert PH, Snyder D (1989) Prevention and treatment of experimental prostate cancer in Lobund-Wistar rats. I. Effects of estradiol, dihydrotestosterone, and castration. Prostate 15:95–103CrossRefPubMed
6.
Zurück zum Zitat Roddam AW, Allen NE, Appleby P, Key TJ (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170–183CrossRefPubMed Roddam AW, Allen NE, Appleby P, Key TJ (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170–183CrossRefPubMed
7.
Zurück zum Zitat Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55:310–320CrossRefPubMed Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55:310–320CrossRefPubMed
8.
Zurück zum Zitat Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA (2005) Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 97:1204–1210CrossRefPubMed Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA (2005) Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 97:1204–1210CrossRefPubMed
9.
Zurück zum Zitat Andersson AM, Jorgensen N, Frydelund-Larsen L, Rajpert-De Meyts E, Skakkebaek NE (2004) Impaired Leydig cell function in infertile men: a study of 357 idiopathic infertile men and 318 proven fertile controls. J Clin Endocrinol Metab 89:3161–3167CrossRefPubMed Andersson AM, Jorgensen N, Frydelund-Larsen L, Rajpert-De Meyts E, Skakkebaek NE (2004) Impaired Leydig cell function in infertile men: a study of 357 idiopathic infertile men and 318 proven fertile controls. J Clin Endocrinol Metab 89:3161–3167CrossRefPubMed
10.
Zurück zum Zitat Pavlovich CP, King P, Goldstein M, Schlegel PN (2001) Evidence of a treatable endocrinopathy in infertile men. J Urol 165:837–841CrossRefPubMed Pavlovich CP, King P, Goldstein M, Schlegel PN (2001) Evidence of a treatable endocrinopathy in infertile men. J Urol 165:837–841CrossRefPubMed
11.
Zurück zum Zitat Skakkebaek NE, Rajpert-De Meyts E, Main KM (2001) Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 16:972–978CrossRefPubMed Skakkebaek NE, Rajpert-De Meyts E, Main KM (2001) Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 16:972–978CrossRefPubMed
12.
Zurück zum Zitat Giwercman A, Richiardi L, Kaijser M, Ekbom A, Akre O (2005) Reduced risk of prostate cancer in men who are childless as compared to those who have fathered a child: a population based case-control study. Int J Cancer 115:994–997CrossRefPubMed Giwercman A, Richiardi L, Kaijser M, Ekbom A, Akre O (2005) Reduced risk of prostate cancer in men who are childless as compared to those who have fathered a child: a population based case-control study. Int J Cancer 115:994–997CrossRefPubMed
13.
Zurück zum Zitat Jorgensen KT, Pedersen BV, Johansen C, Frisch M (2008) Fatherhood status and prostate cancer risk. Cancer 112:919–923CrossRefPubMed Jorgensen KT, Pedersen BV, Johansen C, Frisch M (2008) Fatherhood status and prostate cancer risk. Cancer 112:919–923CrossRefPubMed
14.
Zurück zum Zitat Manjer J, Carlsson S, Elmstahl S et al (2001) The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10:489–499CrossRefPubMed Manjer J, Carlsson S, Elmstahl S et al (2001) The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10:489–499CrossRefPubMed
15.
Zurück zum Zitat Andersson SO, Wolk A, Bergstrom R et al (1997) Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 89:385–389CrossRefPubMed Andersson SO, Wolk A, Bergstrom R et al (1997) Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 89:385–389CrossRefPubMed
16.
Zurück zum Zitat Hickey K, Do KA, Green A (2001) Smoking and prostate cancer. Epidemiol Rev 23:115–125PubMed Hickey K, Do KA, Green A (2001) Smoking and prostate cancer. Epidemiol Rev 23:115–125PubMed
17.
Zurück zum Zitat Dennis LK, Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13:72–79CrossRefPubMed Dennis LK, Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13:72–79CrossRefPubMed
18.
Zurück zum Zitat Platz EA, Leitzmann MF, Rimm EB, Willett WC, Giovannucci E (2004) Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. Am J Epidemiol 159:444–453CrossRefPubMed Platz EA, Leitzmann MF, Rimm EB, Willett WC, Giovannucci E (2004) Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. Am J Epidemiol 159:444–453CrossRefPubMed
19.
Zurück zum Zitat Mouw T, Koster A, Wright ME et al (2008) Education and risk of cancer in a large cohort of men and women in the United States. PLoS ONE 3:e3639CrossRefPubMed Mouw T, Koster A, Wright ME et al (2008) Education and risk of cancer in a large cohort of men and women in the United States. PLoS ONE 3:e3639CrossRefPubMed
20.
Zurück zum Zitat Hull MG, Glazener CM, Kelly NJ et al (1985) Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 291:1693–1697CrossRef Hull MG, Glazener CM, Kelly NJ et al (1985) Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 291:1693–1697CrossRef
21.
Zurück zum Zitat Garne JP, Aspegren K, Moller T (1995) Validity of breast cancer registration from one hospital into the Swedish National Cancer Registry 1971–1991. Acta Oncol 34:153–156CrossRefPubMed Garne JP, Aspegren K, Moller T (1995) Validity of breast cancer registration from one hospital into the Swedish National Cancer Registry 1971–1991. Acta Oncol 34:153–156CrossRefPubMed
22.
Zurück zum Zitat Madersbacher S, Schatzl G, Bieglmayer C et al (2002) Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology 60:869–874CrossRefPubMed Madersbacher S, Schatzl G, Bieglmayer C et al (2002) Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology 60:869–874CrossRefPubMed
23.
Zurück zum Zitat Miller LR, Partin AW, Chan DW et al (1998) Influence of radical prostatectomy on serum hormone levels. J Urol 160:449–453CrossRefPubMed Miller LR, Partin AW, Chan DW et al (1998) Influence of radical prostatectomy on serum hormone levels. J Urol 160:449–453CrossRefPubMed
24.
Zurück zum Zitat Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G (2002) Association between prostate cancer and serum testosterone levels. Prostate 53:179–182CrossRefPubMed Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G (2002) Association between prostate cancer and serum testosterone levels. Prostate 53:179–182CrossRefPubMed
25.
Zurück zum Zitat Imamoto T, Suzuki H, Yano M et al (2008) The role of testosterone in the pathogenesis of prostate cancer. Int J Urol 15:472–480CrossRefPubMed Imamoto T, Suzuki H, Yano M et al (2008) The role of testosterone in the pathogenesis of prostate cancer. Int J Urol 15:472–480CrossRefPubMed
26.
Zurück zum Zitat Sinnecker GH, Hiort O, Nitsche EM, Holterhus PM, Kruse K (1997) Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group. Eur J Pediatr 156:7–14CrossRefPubMed Sinnecker GH, Hiort O, Nitsche EM, Holterhus PM, Kruse K (1997) Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group. Eur J Pediatr 156:7–14CrossRefPubMed
27.
Zurück zum Zitat Marks LS, Mazer NA, Mostaghel E et al (2006) Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296:2351–2361CrossRefPubMed Marks LS, Mazer NA, Mostaghel E et al (2006) Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296:2351–2361CrossRefPubMed
28.
Zurück zum Zitat Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K (2006) Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 176:1387–1391CrossRefPubMed Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K (2006) Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 176:1387–1391CrossRefPubMed
29.
Zurück zum Zitat Heracek J, Hampl R, Hill M et al (2007) Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 72:375–380CrossRefPubMed Heracek J, Hampl R, Hill M et al (2007) Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 72:375–380CrossRefPubMed
30.
Zurück zum Zitat Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224CrossRefPubMed Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224CrossRefPubMed
31.
Zurück zum Zitat Andriole GL, Bostwick DG, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202CrossRefPubMed Andriole GL, Bostwick DG, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202CrossRefPubMed
Metadaten
Titel
Male infertility and prostate cancer risk: a nested case–control study
verfasst von
Yasir Ruhayel
Aleksander Giwercman
David Ulmert
Lars Rylander
Anders Bjartell
Jonas Manjer
Göran Berglund
Yvonne L. Giwercman
Publikationsdatum
01.10.2010
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 10/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9592-8

Weitere Artikel der Ausgabe 10/2010

Cancer Causes & Control 10/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.